A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
Active, not recruiting · Phase 3 · NCT06290128
Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
At a glance
- Research payments reported, 2025
- $678,914
- U.S. investigators named
- 19
- Sites paid
- 20
- Planned or actual enrollment
- 109
About the trial
- Sponsor
- Sanofi
- Tested
- Riliprubart (drug), Placebo (drug), Riliprubart (drug), Placebo (drug)
- Dates
- Started 2024-07-12; completion 2027-10-31
- Results posted
- Not yet
The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care. The study duration will be for a maximum of 111 weeks including screening, treatment phases, and follow-up.
From ClinicalTrials.gov, last updated 2026-08-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $678,914 in research payments for this study in 2025 (42 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Said R. Beydoun, M.D. Neurology · Los Angeles, CA
- Jeffrey Mullen, MD Physical Medicine & Rehabilitation (PM&R) · Orange, CA
- Bhaskar Roy, MBBS Physical Medicine & Rehabilitation (PM&R) · New Haven, CT
- Richard T. Wlodarski, MD Neurology · Glenview, IL
- Mamatha Pasnoor, MD Neurology · Kansas City, KS
- Ariel O. Antezana Neurology · Alexandria, LA
- Ehtesham Khalid, M.D, MRCP, FCPS Physical Medicine & Rehabilitation (PM&R) · New Orleans, LA
- Reza Seyedsadjadi, M.D. Neurology · Boston, MA
- Ahmet Hoke, M.D. Neurology · Baltimore, MD
- Amit Sachdev, M.D., MS Neurology · East Lansing, MI
- Lawrence A. Zeidman, M.D. Neurology · Detroit, MI
- Jeffrey A. Allen, M.D. Neurology · Minneapolis, MN
- Charles A. Roach, MD Neurology · Saint Louis, MO
- Thomas H. Brannagan III, MD Neurology · New York, NY
- Hani A. Kushlaf, MD Neurology · Cincinnati, OH
- Anthony P. Zampino Student in an Organized Health Care Education/Training Program · Cleveland, OH
- Chafic Karam, M.D. Neurology · Portland, OR
- Yessar M. Hussain, M.D. Physical Medicine & Rehabilitation (PM&R) · Austin, TX
- Rup Tandan, M.D., FRCP Neurology · Burlington, VT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Hospital of Univ of Pennsylvania, PA $137,315
- Yale University Attn Treasury Services $94,596
- National Neuromuscular Research Institute PLLC $41,500
- Uci Health-Orange, CA $39,806
- Michigan State University Center for Bleeding and Cloting Dis $36,539
- The University of Cincinnati Foundation $35,445
- Uh Cleveland Medical Center, OH $32,420
- The Trustees of Columbia University in The City of New York $32,018
- Regents of the University of Minnesota $31,431
- Johns Hopkins University $31,257
- Ochsner Medical Center Acute, LA $26,740
- Henry Ford Health Hospital, MI $25,400
- Keck Hospital of Usc, CA $21,700
- University of Kansas Medical Center Research Inst Inc $19,385
- Massachusetts General Hospital Attn Research Finance Attn 2021a $16,800
- University of Vermont Medical Center $16,713
- Northshore University Healthsystem - Evanston Hospital, IL $16,050
- Investigator Research Network Llc $14,556
- The Washington University Attn Anadkatact17967p240336 $6,244
- Washington University $3,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.